Free Trial
NASDAQ:SPRO

Spero Therapeutics (SPRO) Stock Price, News & Analysis

Spero Therapeutics logo
$2.84 -0.20 (-6.41%)
Closing price 03:58 PM Eastern
Extended Trading
$2.92 +0.07 (+2.64%)
As of 04:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Spero Therapeutics Stock (NASDAQ:SPRO)

Key Stats

Today's Range
$2.87
$3.07
50-Day Range
$0.58
$3.04
52-Week Range
$0.51
$3.22
Volume
1.63 million shs
Average Volume
1.22 million shs
Market Capitalization
$159.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00
Consensus Rating
Moderate Buy

Company Overview

Spero Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
78th Percentile Overall Score

SPRO MarketRank™: 

Spero Therapeutics scored higher than 78% of companies evaluated by MarketBeat, and ranked 219th out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Spero Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Spero Therapeutics has received no research coverage in the past 90 days.

  • Read more about Spero Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Spero Therapeutics are expected to grow in the coming year, from ($1.20) to ($0.79) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Spero Therapeutics is -2.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Spero Therapeutics is -2.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Spero Therapeutics has a P/B Ratio of 3.35. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Spero Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    3.05% of the float of Spero Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Spero Therapeutics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Spero Therapeutics has recently decreased by 53.74%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Spero Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Spero Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.05% of the float of Spero Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Spero Therapeutics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Spero Therapeutics has recently decreased by 53.74%, indicating that investor sentiment is improving significantly.
  • Search Interest

    Only 3 people have searched for SPRO on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Spero Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 5.50% of the stock of Spero Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 25.60% of the stock of Spero Therapeutics is held by institutions.

  • Read more about Spero Therapeutics' insider trading history.
Receive SPRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Spero Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SPRO Stock News Headlines

Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.
See More Headlines

SPRO Stock Analysis - Frequently Asked Questions

Spero Therapeutics' stock was trading at $1.03 at the start of the year. Since then, SPRO shares have increased by 176.2% and is now trading at $2.8450.

Spero Therapeutics, Inc. (NASDAQ:SPRO) posted its quarterly earnings data on Tuesday, May, 13th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.30. The company earned $5.87 million during the quarter, compared to analyst estimates of $11 million. Spero Therapeutics had a negative net margin of 156.48% and a negative trailing twelve-month return on equity of 123.50%.

Spero Therapeutics (SPRO) raised $75 million in an initial public offering (IPO) on Thursday, November 2nd 2017. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Stifel served as the underwriters for the IPO and Oppenheimer & Co. was co-manager.

Top institutional shareholders of Spero Therapeutics include Capital Asset Advisory Services LLC (0.06%). Insiders that own company stock include Aquilo Capital Management, Llc, Sath Shukla, Esther Rajavelu, Ankit Mahadevia, Kamal Hamed and Timothy Keutzer.
View institutional ownership trends
.

Shares of SPRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Spero Therapeutics investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), Meta Platforms (META), NVIDIA (NVDA), Editas Medicine (EDIT) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
5/13/2025
Today
7/10/2025
Next Earnings (Estimated)
8/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SPRO
CIK
1701108
Fax
N/A
Employees
150
Year Founded
2013

Price Target and Rating

High Price Target
$5.00
Low Price Target
$5.00
Potential Upside/Downside
+75.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.28)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$68.57 million
Net Margins
-156.48%
Pretax Margin
-156.48%
Return on Equity
-123.50%
Return on Assets
-58.96%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.56
Quick Ratio
2.56

Sales & Book Value

Annual Sales
$47.98 million
Price / Sales
3.32
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.85 per share
Price / Book
3.35

Miscellaneous

Outstanding Shares
55,910,000
Free Float
52,836,000
Market Cap
$159.06 million
Optionable
Optionable
Beta
1.33

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:SPRO) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners